Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Oncol Lett
2022 May 01;235:143. doi: 10.3892/ol.2022.13262.
Show Gene links
Show Anatomy links
TPX2 regulated by miR-29c-3p induces cell proliferation in osteosarcoma via the AKT signaling pathway.
Zhu D
,
Xu X
,
Zhang M
,
Wang T
.
???displayArticle.abstract???
The present study aimed to investigate the significance of targeting protein for Xenopus kinesin-like protein 2 (TPX2) expression in osteosarcoma. First, the TPX2 expression and survival analysis data were evaluated from The Cancer Genome Atlas (TCGA) database. Next, reverse transcription-quantitative PCR was used to explore the expression of TPX2 in osteosarcoma tissues. The observed potential target relationship between TPX2 and microRNA (miR)-29c-3p was verified using TargetScan and luciferase reporter assays. Kaplan-Meier survival analysis was used to determine associations between TPX2 expression levels and survival prognosis. TPX2 small interfering RNA was successfully constructed and transfected into osteosarcoma cell lines. The effects of TPX2 on osteosarcoma cell proliferation were then detected by MTT assay. In addition, the expression levels of AKT signaling pathway-associated proteins were identified by western blot analysis. The expression of TPX2 was upregulated and the expression of miR-29c-3p was downregulated in osteosarcoma. High expression of TPX2 was linked to a poor prognosis. Using luciferase assay and the miRNA mimic and inhibitors, miR-29c-3p was able to target and repress TPX2, and siRNA knockdown of TPX2 resulted in the inhibition of osteosarcoma cell proliferation by affecting the AKT pathway. Overall, the study showed that miR-29c-3p could inhibit the proliferation of osteosarcoma cells via TPX2 downregulation, and that TPX2 and miR-29c-3p may serve as promising prognostic indicators.
Bishop,
Future directions in the treatment of osteosarcoma.
2016, Pubmed
Bishop,
Future directions in the treatment of osteosarcoma.
2016,
Pubmed
Cai,
Identification of five hub genes as monitoring biomarkers for breast cancer metastasis in silico.
2019,
Pubmed
Carter,
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.
2006,
Pubmed
Cates,
Simple staging system for osteosarcoma performs equivalently to the AJCC and MSTS systems.
2018,
Pubmed
Chen,
Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in breast cancer.
2018,
Pubmed
,
Xenbase
Eaton,
Osteosarcoma.
2021,
Pubmed
Gao,
Sinomenine restrains breast cancer cells proliferation, migration and invasion via modulation of miR-29/PDCD-4 axis.
2019,
Pubmed
Glover,
Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation.
2017,
Pubmed
Gomes-Filho,
Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
2020,
Pubmed
Hsu,
TPX2 expression is associated with cell proliferation and patient outcome in esophageal squamous cell carcinoma.
2014,
Pubmed
Huang,
TPX2 silencing exerts anti‑tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway.
2019,
Pubmed
,
Xenbase
Huo,
Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
2020,
Pubmed
Jiang,
TPX2 regulates tumor growth in human cervical carcinoma cells.
2014,
Pubmed
,
Xenbase
Joko,
PRRX1 promotes malignant properties in human osteosarcoma.
2021,
Pubmed
Knott,
Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.
2019,
Pubmed
Lengauer,
Genetic instabilities in human cancers.
1998,
Pubmed
Li,
Interleukin-22 secreted by cancer-associated fibroblasts regulates the proliferation and metastasis of lung cancer cells via the PI3K-Akt-mTOR signaling pathway.
2019,
Pubmed
Liu,
miR-29 promotes osteosarcoma cell proliferation and migration by targeting PTEN.
2019,
Pubmed
Livak,
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
2001,
Pubmed
Ma,
MicroRNA-29c-3p inhibits osteosarcoma cell proliferation through targeting PIK3R3.
2020,
Pubmed
Marina,
Biology and therapeutic advances for pediatric osteosarcoma.
2004,
Pubmed
Mu,
Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition.
2019,
Pubmed
Nelson,
AKT regulates BRCA1 stability in response to hormone signaling.
2010,
Pubmed
Perry,
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
2014,
Pubmed
Redlak,
Targeting PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to deoxycholate-induced apoptosis.
2011,
Pubmed
Sadykova,
Epidemiology and Risk Factors of Osteosarcoma.
2020,
Pubmed
Shigeishi,
Expression of TPX2 in salivary gland carcinomas.
2009,
Pubmed
Song,
Circular RNA hsa_circ_0001564 regulates osteosarcoma proliferation and apoptosis by acting miRNA sponge.
2018,
Pubmed
Taherdangkoo,
miR-485-3p suppresses colorectal cancer via targeting TPX2.
2020,
Pubmed
Tian,
Combined analysis of DNA methylation and gene expression profiles of osteosarcoma identified several prognosis signatures.
2018,
Pubmed
Wang,
CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis.
2019,
Pubmed
Wieczorek,
Microtubule-associated proteins control the kinetics of microtubule nucleation.
2015,
Pubmed
Yao,
MicroRNA miR-29c-3p modulates FOS expression to repress EMT and cell proliferation while induces apoptosis in TGF-β2-treated lens epithelial cells regulated by lncRNA KCNQ1OT1.
2020,
Pubmed
Yun,
HCP5 promotes colon cancer development by activating AP1G1 via PI3K/AKT pathway.
2019,
Pubmed
